Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The MUC5B promoter variant results in proteomic changes in the nonfibrotic lung
Jeremy A. Herrera, … , Ivana V. Yang, David A. Schwartz
Jeremy A. Herrera, … , Ivana V. Yang, David A. Schwartz
Published June 17, 2025
Citation Information: JCI Insight. 2025;10(14):e189636. https://doi.org/10.1172/jci.insight.189636.
View: Text | PDF
Research Article Genetics Pulmonology

The MUC5B promoter variant results in proteomic changes in the nonfibrotic lung

  • Text
  • PDF
Abstract

The gain-of-function MUC5B promoter variant is the dominant risk factor for the development of idiopathic pulmonary fibrosis (IPF). However, its impact on protein expression in both nonfibrotic control and IPF lung specimens has not been well characterized. Utilizing laser capture microdissection coupled to mass spectrometry, we investigated the proteomic profiles of airway and alveolar epithelium in nonfibrotic controls (n = 12) and IPF specimens (n = 12), stratified by the MUC5B promoter variant. Through qualitative and quantitative analyses, as well as pathway analysis and immunohistological validation, we have identified a distinct MUC5B-associated protein profile. Notably, the nonfibrotic control alveoli exhibited substantial MUC5B-associated protein changes, with an increase in IL-3 signaling. Additionally, we found that epithelial cells overlying IPF fibroblastic foci clustered closely to alveolar epithelia and expressed proteins associated with cellular stress pathways. In conclusion, our findings suggest that the MUC5B promoter variant leads to protein changes in alveolar and airway epithelium that appear to be associated with initiation and progression of lung fibrosis.

Authors

Jeremy A. Herrera, Mark Maslanka, Rachel Z. Blumhagen, Rachel Blomberg, Nyan Ye Lwin, Janna Brancato, Carlyne D. Cool, Jonathan P. Huber, Jonathan S. Kurche, Chelsea M. Magin, Kirk C. Hansen, Ivana V. Yang, David A. Schwartz

×

Figure 1

Impact of the MUC5B promoter variant on nonfibrotic control lung.

Options: View larger image (or click on image) Download as PowerPoint
Impact of the MUC5B promoter variant on nonfibrotic control lung.
(A and...
(A and B) Volcano plots comparing the MUC5B promoter variant and WT allele in nonfibrotic control (A) small airways and (B) alveoli, showing the negative natural log of adjusted P values (0.05) for each protein. (C) Representative images for the IHC against phosphorylated STAT5A at Tyr694 on nonfibrotic control lungs. Scale bars: 50 μm. (D) Quantification of C showing the percentage of positive cells (n = 12, balanced for MUC5B; 5 fields of view per patient with a total of 22,999 counted nuclei). **P < 0.005 by unpaired, 2-tailed t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts